ACER3 and metabolic dysfunction-associated steatohepatitis: In conclusion, we for the first time demonstrate that ACER3 has a pathological role in the progression of PEWD-induced NASH by regulating the hepatic levels of C18:1-ceramide that may counteract the effects of palmitate on oxidative stress in hepatocyte.